Technical Analysis for VRTX - Vertex Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
grade A 160.72 -0.14% -0.22
VRTX closed down 0.14 percent on Friday, February 16, 2018, on 55 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
5 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical VRTX trend table...

Date Alert Name Type % Chg
Feb 16 MACD Bullish Centerline Cross Bullish 0.00%
Feb 16 NR7 Range Contraction 0.00%
Feb 16 NR7-2 Range Contraction 0.00%
Feb 16 Doji - Bearish? Reversal 0.00%
Feb 16 Multiple of Ten Bullish Other 0.00%
Feb 16 Wide Bands Range Expansion 0.00%
Feb 15 New Uptrend Bullish -0.14%
Feb 15 NR7 Range Contraction -0.14%
Feb 15 Multiple of Ten Bullish Other -0.14%
Feb 15 Wide Bands Range Expansion -0.14%

Older signals for VRTX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Its products include telaprevir for the treatment of adults with genotype 1 hepatitis C virus (HCV) infection, which is marketed in the United States and Canada under the INCIVEK brand name; and ivacaftor for the treatment of cystic fibrosis that is marketed in the United States, Canada, and Europe under the KALYDECO brand name. The company, through its collaboration agreement with Janssen Pharmaceutica, N.V., also markets telaprevir in Europe and other countries in Janssen's territories under the INCIVO brand name, as well as in Japan under TELAVIC brand name. It is also developing drug candidates for the treatment of cystic fibrosis, including VX-809, which is in Phase III clinical trial and VX-661 that is in Phase II clinical trial; and drug candidates for the treatment of HCV infection, such as VX-135 (ALS-2200), which is in Phase II clinical trial and VX-222 that is in Phase II clinical trial. In addition, the company develops VX-509, which is in Phase II clinical trial for the treatment of autoimmune disease; and VX-787 that is in Phase II clinical trial for the treatment of influenza. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Is VRTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 174.955
52 Week Low 84.39
Average Volume 1,760,207
200-Day Moving Average 145.5436
50-Day Moving Average 154.6362
20-Day Moving Average 161.529
10-Day Moving Average 155.971
Average True Range 5.2027
ADX 25.73
+DI 22.0
-DI 20.38
Chandelier Exit (Long, 3 ATRs ) 159.3469
Chandelier Exit (Short, 3 ATRs ) 161.8181
Upper Bollinger Band 174.1348
Lower Bollinger Band 148.9232
Percent B (%b) 0.47
BandWidth 15.608095
MACD Line 0.1098
MACD Signal Line 0.756
MACD Histogram -0.6462
Fundamentals Value
Market Cap 40.53 Billion
Num Shares 252 Million
EPS 1.04
Price-to-Earnings (P/E) Ratio 154.54
Price-to-Sales 17.01
Price-to-Book 21.57
PEG Ratio 1.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 164.74
Resistance 3 (R3) 164.74 163.41 164.07
Resistance 2 (R2) 163.41 162.38 163.41 163.85
Resistance 1 (R1) 162.06 161.75 161.40 162.06 163.62
Pivot Point 160.73 160.73 160.39 160.73 160.73
Support 1 (S1) 159.38 159.70 158.72 159.38 157.82
Support 2 (S2) 158.05 159.07 158.05 157.59
Support 3 (S3) 156.70 158.05 157.37
Support 4 (S4) 156.70